Fig. 3.

Intranasal administration of rCCL17 improved short-term neurological function and reduced brain edema at 72 h after ICH. (A) Modified Garcia test; (B) left forelimb placement test; (C) corner turn test; (D) brain edema at 24-h post-ICH; (E) brain edema at 72-h post-ICH. Short-term neurological results showed that rCCL17 treatment at the dosage of 30 and 90 μg/kg improved short-term neurological function significantly, compared to vehicle and low dosage groups. So, we further chose the middle dosage for brain edema measurements. *p < 0.05 versus sham, @p < 0.05 versus ICH + vehicle, mean ± SD, two-way repeated measures ANOVA (A, B, C), One-way ANOVA (D, E), Tukey test, n = 6/group